Company intelligence / Profile preview
CSPC NBP Pharmaceutical
Shijiazhuang, Hebei, China
- Ownership
- Private
- Development stage
- Other
01
Overview
The company’s flagship product "dl‑3‑n‑Butylphthalide" ("NBP") leads the global market for stroke management. It has treated over 10 million patients since launch. The drug has orphan drug designation from the FDA and is in Phase III trials in the US. The company also produces a range of small molecules and biologics targeting CNS disorders, oncology indications such as myelosuppression support during chemotherapy ("Jinyouli"), anti-infectives and cardiovascular disease. Several biosimilars are approved or under development.
- Therapeutic areas
- ImmunologyCardiovascular
- Modalities
- Small moleculeMonoclonal antibodyAntibody-drug conjugateBiosimilarBispecific antibody
- Industry
- Pharma
02
Drug pipeline
1 asset03
Partnerships
Harbour BioMed – exclusive rights transfer agreement for batoclimab/HBM9161 development/commercialization in Greater China region.Verastem Oncology – licensing agreement for COPIKTRA®(duvelisib) oral PI3K inhibitor.Other collaborations with academic institutions not specified by name.
Beyond the preview
Go deeper on CSPC NBP Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CSPC NBP Pharmaceutical.